Human IL-33 PicoKine® Quick ELISA Kit
FEK0929
96 wells/kit, with removable strips.
*Question: How many samples can I assay/run in this kit?
Human IL-33 PicoKine® Quick ELISA Kit (90 minutes, 96 Tests). Human IL33 in cell culture supernatants, serum, plasma (heparin, EDTA) and cell lysates. Sensitivity: 10pg/ml. The brand Picokine indicates this is a premium quality ELISA kit. Each Picokine kit delivers precise quantification, high sensitivity, and excellent reproducibility. Only our most reliable and effective kits qualify as Picokine, guaranteeing top-tier results for your assays.
Store at 4~C for 6 months. (Ships with gel ice, can store for up to 3 days in room temperature. Refrigerate upon receipt.)
Human IL-33 PicoKine® Quick ELISA Kit (Boster Biological Technology, Pleasanton CA, USA, Catalog # FEK0929)
See Datasheet for details
Expression system for standard: E.coli; Immunogen sequence: S112-T270
The capture antibody is monoclonal antibody from mouse and the detection antibody is polyclonal antibody from goat.
<10 pg/ml
15.6 pg/ml - 1,000 pg/ml

See datasheet of FEK0929 for more details
There is no detectable cross-reactivity with other relevant proteins.
FEK0929 is reactive to IL33 in Human samples
cell culture supernatants, serum, plasma (heparin, EDTA) and cell lysates.
FEK0929 is guaranteed for ELISA in Human by Boster Guarantee
See how Boster Bio validate our ELISA kits: ELISA Validation Information
Interleukin 33 (IL-33) is a cytokine belonging to the IL-1 superfamily. The IL33 gene maps to chromosome 9p24.1 by using of genomic database analysis. Recombinant mature human IL33 bound to ST2. The induction of type 2 cytokines by IL-33 in vivo is believed to induce the severe pathological changes observed in mucosal organs following administration of IL-33. IL33, an alarmin released from necrotic cells, is necessary for potent CD8 + T cell (CTL) responses to replicating, prototypic RNA, and DNA viruses in mice. IL33 prevented the downregulation of CXCR2 and inhibition of chemotaxis induced by activation of TLR4, and found that IL33 reverses the TLR4-induced reduction of CXCR2 expression via the inhibition of expression of GRK2.
| Catalog number | Description | Quantity | Volume |
|---|---|---|---|
| FEK0929-CAP | Anti-tag Pre-coated 96-well Strip Microplate | 1 | 12 strips of 8 wells |
| EK0929-ST | Human IL33 Standard | 2 | 10 ng/tube |
| FEK0929-A | Human IL33 Antibody A | 1 | 3ml |
| FEK0929-B | Human IL33 Antibody B | 1 | 3ml |
| AR1106-1 | Sample Diluent | 1 | 15ml |
| AR1106-7 | TBS-T Wash Buffer (25x) | 1 | 12ml |
| AR1104 | Color Developing Reagent (TMB) | 1 | 10ml |
| AR1105 | Stop Solution | 1 | 10ml |
| PLA-SEA | Adhesive Plate Sealers | 2 | Piece |
*The kit components are not available for individual purchase.
| Concentration (pg/ml) | 0 | 15.6 | 31.2 | 62.5 | 125 | 250 | 500 | 1000 |
| O.D. | 0.011 | 0.103 | 0.168 | 0.312 | 0.609 | 0.933 | 1.546 | 2.068 |

Human IL-33 PicoKine ELISA Kit standard curve
We measured random samples of Human IL-33 PicoKine® Quick ELISA Kit within the same batch/lot to ensure the consistency of the kits' performances. ELISA intra assay consistency is measured using wells from the same plate/assay kit. ELISA inter assay consistency is measured using wells from different plates from the same batch production/lot.
| Intra-Assay Precision | Inter-Assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 16 | 16 | 16 | 24 | 24 | 24 |
| Mean (pg/ml) | 30 | 260 | 484 | 28 | 282 | 511 |
| Standard deviation | 1.74 | 17.98 | 37.75 | 1.76 | 22.27 | 47.89 |
| CV (%) | 5.8% | 7.9% | 7.8% | 7.9% | 7.9% | 9% |
We ensure reproducibility by testing three samples with differing concentrations of IL33 in ELISA kits from four different production batches/lots.
| Lots | Lot 1 (pg/ml) | Lot 2 (pg/ml) | Lot 3 (pg/ml) | Lot 4 (pg/ml) | Mean (pg/ml) | Standard Deviation | CV (%) |
|---|---|---|---|---|---|---|---|
| Sample 1 | 30 | 31 | 28 | 32 | 30 | 1.47 | 4.9% |
| Sample 2 | 260 | 230 | 231 | 235 | 239 | 12.26 | 5.1% |
| Sample 3 | 484 | 481 | 517 | 495 | 494 | 14.13 | 2.8% |